alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

31,780 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 126–150 of 201 studies with an author at Stanford University (US) · free to read (page 6 of 9) · 31,780 in the whole library · How the 0–100 score works

Download bibliography of these 201 studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Other institutions

From OpenAlex; 17,251 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Beclin 1 gene transfer activates autophagy and ameliorates the neurodegenerative pathology in alpha-synuclein models of Parkinson's and Lewy body diseases

✓ Peer-reviewed alzhub usefulness score 52 out of 100. The Journal of neuroscience : the official journal of the Society for Neuroscience 2009-10-01

Accumulation of the synaptic protein alpha-synuclein (alpha-syn) is a hallmark of Parkinson's disease (PD) and Lewy body disease (LBD), a heterogeneous group of disorders with dementia and parkinsonism, where Alzheimer's disease and PD interact. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Proteomics of brain, CSF, and plasma identifies molecular signatures for distinguishing sporadic and genetic Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Science translational medicine 2023-07-05

Proteomic studies for Alzheimer's disease (AD) are instrumental in identifying AD pathways but often focus on single tissues and sporadic AD cases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

The Revised National Alzheimer's Coordinating Center's Neuropathology Form-Available Data and New Analyses

✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neuropathology and experimental neurology 2018-08-01

Neuropathologic evaluation remains the gold standard for determining the presence and severity of aging-related neurodegenerative diseases. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Walking stabilizes cognitive functioning in Alzheimer's disease (AD) across one year

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Archives of gerontology and geriatrics 2012-09-05

AD is a public health epidemic, which seriously impacts cognition, mood and daily activities; however, one type of activity, exercise, has been shown to alter these states. 3 key findings →

Participants: 104 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Apolipoprotein E Mimetic Peptide CN-105 and Postoperative Delirium in Older Patients

✓ Peer-reviewed alzhub usefulness score 51 out of 100. JAMA Network Open 2026-04-03

Among 203 enrolled patients, 186 (mean [SD] age, 68.7 [5.2] years; 119 males [64.0%]) were randomized (137 to the CN-105 group, 49 to the placebo group) and underwent surgery. 5 key findings →

Design: clinical trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Cryptic splicing in synaptic and membrane excitability genes links TDP-43 loss to neuronal dysfunction

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Science Translational Medicine 2026-06-03

Using human stem cell-derived neurons, we show that TDP-43 reduction induces cryptic splicing and downregulation of these genes, resulting in impaired excitability and synaptic transmission. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Speed of Processing Training for Stress Adaptation in Caregivers of a Family Member With Dementia: A Randomized Controlled Trial

✓ Peer-reviewed alzhub usefulness score 51 out of 100. Innovation in Aging 2025-01-01

The VSOP/A group had significantly improved processing speed and attention performance compared to the VE group, and these differences persisted through 6 months postintervention. 4 key findings →

Design: randomized controlled trial Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Insulin resistance and hippocampal volume in women at risk for Alzheimer's disease

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Neurobiology of aging 2009-12-23

Insulin resistance (IR) is the main pathological condition underlying vascular disorders, such as diabetes and cardiovascular disease, which are well established risk factors for cognitive decline and Alzheimer disease (AD). 3 key findings →

Design: longitudinal study Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

"Thinking about it for somebody else": Alzheimer's disease research and proxy decision makers' translation of ethical principles into practice

✓ Peer-reviewed alzhub usefulness score 50 out of 100. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry 2013-02-06

Tensions exist between abstract ethical principles regarding decision-making "standards" and their translation into research decisions. 3 key findings →

Participants: 40 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Concepts for brain aging: resistance, resilience, reserve, and compensation

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer's research & therapy 2019-03-11

A primary goal of research in cognitive impairment and dementia is to understand how some individuals retain sufficient cognitive function for a fulfilling life while many others are robbed of their independence, sometimes their essence, in the last years and decades of life. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Association of Neighborhood‐Level Disadvantage with Antemortem MRI Brain Volumes in a Multi‐site Brain Bank Donor Cohort

✓ Peer-reviewed alzhub usefulness score 50 out of 100. Alzheimer s & Dementia 2025-12-01

A significant ADI × dementia interaction was observed for global atrophy (p = .005) and several other outcomes. 5 key findings →

Design: longitudinal study Participants: 14 Evidence: moderate

Full summary, score breakdown and related studies → Original source Free full text

APOE ε4 worsens hippocampal CA1 apical neuropil atrophy and episodic memory

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Neurology 2014-01-22

The APOE ε4 allele segregated dose-dependently and selectively with CA1-SRLM thinning and worse episodic memory performance in a pool of older subjects across a cognitive spectrum. 4 key findings →

Design: cross-sectional Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Estrogens, episodic memory, and Alzheimer's disease: a critical update

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Seminars in reproductive medicine 2009-04-28

Estrogen-containing hormone therapy initiated during late postmenopause does not improve episodic memory (an important early symptom of Alzheimer's disease), and it increases dementia risk. 1 key finding →

Design: cohort study Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

Dementia After Moderate-Severe Traumatic Brain Injury: Coexistence of Multiple Proteinopathies

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neuropathology and experimental neurology 2018-01-01

We report the clinical, neuroimaging, and neuropathologic characteristics of 2 patients who developed early onset dementia after a moderate-severe traumatic brain injury (TBI). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Effectiveness of Cognitive/Behavioral Small Group Intervention for Reduction of Depression and Stress in Non-Hispanic White and Hispanic/Latino Women Dementia Family Caregivers: Outcomes and Mediators of Change

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of rational-emotive and cognitive-behavior therapy : RET 2008-12-01

This study enrolled 184 middle-aged and older women (95 Non-Hispanic White and 89 Hispanic/Latino) who provided in-home hands-on care to an elderly relative with Alzheimer's disease or another form of dementia. 4 key findings →

Participants: 184 Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Targeting innate immunity for neurodegenerative disorders of the central nervous system

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Journal of neurochemistry 2016-09-01

Neuroinflammation is critically involved in numerous neurodegenerative diseases, and key signaling steps of innate immune activation hence represent promising therapeutic targets. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomized / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multicenter collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 31,780 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,780 records, built mostly from automated pulls of Europe PMC (66% of the library) and OpenAlex (16%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,052 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed    Where this research is being discussed: events